{"id":"NCT00566735","sponsor":"Massachusetts General Hospital","briefTitle":"The Use of Galantamine HBr (Reminyl) in Electroconvulsive Therapy: Impact on Mood and Cognitive Functioning","officialTitle":"The Use of Galantamine HBr (Reminyl) in Electroconvulsive Therapy: Impact on Mood and Cognitive Functioning","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2004-07","primaryCompletion":"2008-01","completion":"2008-01","firstPosted":"2007-12-04","resultsPosted":"2012-12-03","lastUpdate":"2012-12-03"},"enrollment":39,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Major Depression","Bipolar Depression","Schizoaffective Disorder"],"interventions":[{"type":"DRUG","name":"Razadyne","otherNames":["Galantamine"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"1","type":"PLACEBO_COMPARATOR"},{"label":"2, Galantamine","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of the study is to see if galantamine HBr (Razadyne) is safe and can help treat problems with thinking and memory caused by electroconvulsive therapy (ECT).","primaryOutcome":{"measure":"Number of Side Effects","timeFrame":"Participants were followed for the duration of hospital stay, an average of 3 weeks","effectByArm":[{"arm":"Placebo","deltaMin":19,"sd":null},{"arm":"Galantamine","deltaMin":13,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":17},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":19},"commonTop":["headache","dizziness","diarrhea","vomiting","nausea"]}}